Puma May Face Marketing Hurdles Even If Neratinib Wins Final Approval
Executive Summary
Neratinib's value as extended adjuvant therapy for HER2-positive breast cancer may be diminished if Roche succeeds in altering the standard of care for initial adjuvant treatment, among other challenges.
You may also be interested in...
Puma's Likely Neratinib EU Knockback May Be Temporary
A positive opinion on the marketing application for Puma's neratinib in the EU is unlikely next month after a recent discussion with regulators failed to satisfy risk-benefit concerns, but more data on controlling diarrhea are expected shortly.
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups
US FDA labeling details the differences in performance of neratinib in adjuvant breast cancer by subgroup, as well as results relative to the timing of Roche's Herceptin, but the drug's indication covers all.